Response Evaluation Criteria in Solid Tumors

Known as: RECIST 
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
BACKGROUND Malignant pleural mesothelioma is a highly aggressive cancer with poor prognosis and few treatment options following… (More)
Is this relevant?
Review
2017
Review
2017
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2015
Highly Cited
2015
PD-1 blockade in tumors with mismatch repair deficiency.
LBA100 Background: Somatic mutations have the potential to be recognized as "non-self" immunogenic antigens. Tumors with genetic… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
PURPOSE This phase I dose-escalation study investigated the maximum-tolerated dose (MTD), safety, preliminary activity… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
PURPOSE Most treatments for patients with metastatic melanoma have a low rate of complete regression and thus overall survival in… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
PURPOSE Adoptive immunotherapy using tumor-infiltrating lymphocytes represents an effective cancer treatment for patients with… (More)
  • table 1
  • table 2
  • figure 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
PURPOSE Immunotherapeutic agents produce antitumor effects by inducing cancer-specific immune responses or by modifying native… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
BACKGROUND Evaluation of response to treatment is a key aspect in cancer therapy. Response Evaluation Criteria in Solid Tumors… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
PURPOSE The two approved treatments for patients with metastatic melanoma, interleukin (IL)-2 and dacarbazine, mediate objective… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2007
Highly Cited
2007
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new…
PURPOSE Response Evaluation Criteria in Solid Tumors (RECIST) are insensitive in evaluating gastrointestinal stromal tumors… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
  • figure 1
Is this relevant?